SequelSEC

Q/C TECHNOLOGIES, INC. QCLS

In Vitro & In Vivo Diagnostic Substances · CIK 0001321834 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$1.78M
Fiscal year ended 2019-09-30
Operating income
-$5.54M
Fiscal year ended 2019-09-30
Free cash flow
Unavailable
Fiscal year ended 2019-09-30

Valuation, from the filing

Public float$3.62MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$0.46Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today.

How this compares in its industry

Percentile among the In Vitro & In Vivo Diagnostic Substances filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Current ratio6.74x87th
Revenue YoY growth-5.3%21th

Q/C TECHNOLOGIES, INC. (QCLS) reported revenue of $1.78M and net income of -$6.39M for the fiscal year ended 2019-09-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Q/C TECHNOLOGIES, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under In Vitro & In Vivo Diagnostic Substances.

Income

Q/C TECHNOLOGIES, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2019-09-30
Revenue$1.78M
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$5.54M
Net income-$6.39M
Research & development$410.09K
Weighted-average diluted sharesUnavailable
Pretax income-$6.37M
Income tax expenseUnavailable
Diluted EPSUnavailable
Selling, general & administrative$4.90M
General & administrative$4.29M
Selling & marketing$618.20K

Balance

Q/C TECHNOLOGIES, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2019-09-30
Cash & equivalents$363.29K
Total assets$4.97M
Current assets$4.32M
Total liabilities$1.37M
Current liabilities$1.37M
Total equity incl. NCI$3.60M
Temporary (mezzanine) equityUnavailable
Inventory$412.06K
Accounts receivable$230.90K
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$1.37M

Cash flow

Q/C TECHNOLOGIES, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2019-09-30
Operating cash flow-$5.21M
Capital expendituresUnavailable
Investing cash flow$1.94M
Financing cash flowUnavailable
Net change in cash-$1.32M
Stock-based compensationUnavailable
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$109.50K

Derived

Q/C TECHNOLOGIES, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2019-09-30
Free cash flowUnavailable
Gross marginUnavailable
Operating margin-311.8%
FCF marginUnavailable
SBC / revenueUnavailable
Current ratio3.14x
Revenue YoY growth-23.6%
Net margin-359.4%
R&D / revenue23.1%
CapEx / revenueUnavailable
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open QCLS in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-12View SEC filing
10-Q · Filed 2026-05-15View SEC filing
10-K · Filed 2026-04-15View SEC filing
10-Q · Filed 2025-11-19View SEC filing
10-Q · Filed 2025-08-19View SEC filing
10-Q · Filed 2025-05-15View SEC filing

Companies in the same industry

ACHV AWHL BMRA BZYR CDIO CLDX ICCC IDXX IMDX LNTH MYGN NEOG

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.